CANN
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
5.44M
MEDIF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
22.84M
Interact to see
Advertisement

CANN vs MEDIF

Header iconCANN vs MEDIF Comparison
Open Charts CANN vs MEDIFBanner chart's image
TREES
Price$0.05
Change-$0.00 (-0.00%)
Volume$140.12K
Capitalization5.44M
Medipharm Labs
Price$0.05
Change-$0.00 (-0.00%)
Volume$48.26K
Capitalization22.84M
CANN vs MEDIF Comparison Chart in %
Loading...
CANN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CANN vs. MEDIF commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANN is a Hold and MEDIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (CANN: $0.05 vs. MEDIF: $0.05)
Brand notoriety: CANN and MEDIF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CANN: 64% vs. MEDIF: 40%
Market capitalization -- CANN: $5.44M vs. MEDIF: $22.84M
CANN [@Pharmaceuticals: Generic] is valued at $5.44M. MEDIF’s [@Pharmaceuticals: Generic] market capitalization is $22.84M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANN’s FA Score shows that 0 FA rating(s) are green whileMEDIF’s FA Score has 0 green FA rating(s).

  • CANN’s FA Score: 0 green, 5 red.
  • MEDIF’s FA Score: 0 green, 5 red.
According to our system of comparison, CANN is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANN’s TA Score shows that 5 TA indicator(s) are bullish while MEDIF’s TA Score has 3 bullish TA indicator(s).

  • CANN’s TA Score: 5 bullish, 4 bearish.
  • MEDIF’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CANN is a better buy in the short-term than MEDIF.

Price Growth

CANN (@Pharmaceuticals: Generic) experienced а +40.85% price change this week, while MEDIF (@Pharmaceuticals: Generic) price change was -9.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEDIF($22.8M) has a higher market cap than CANN($5.44M). CANN YTD gains are higher at: 177.778 vs. MEDIF (25.327). CANN has higher annual earnings (EBITDA): 619K vs. MEDIF (-4.75M). MEDIF has more cash in the bank: 8.44M vs. CANN (245K). MEDIF has less debt than CANN: MEDIF (125K) vs CANN (17.4M). MEDIF has higher revenues than CANN: MEDIF (43M) vs CANN (14.5M).
CANNMEDIFCANN / MEDIF
Capitalization5.44M22.8M24%
EBITDA619K-4.75M-13%
Gain YTD177.77825.327702%
P/E RatioN/AN/A-
Revenue14.5M43M34%
Total Cash245K8.44M3%
Total Debt17.4M125K13,920%
FUNDAMENTALS RATINGS
CANN vs MEDIF: Fundamental Ratings
CANN
MEDIF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
3559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANN's Valuation (67) in the null industry is in the same range as MEDIF (91). This means that CANN’s stock grew similarly to MEDIF’s over the last 12 months.

CANN's Profit vs Risk Rating (100) in the null industry is in the same range as MEDIF (100). This means that CANN’s stock grew similarly to MEDIF’s over the last 12 months.

MEDIF's SMR Rating (95) in the null industry is in the same range as CANN (99). This means that MEDIF’s stock grew similarly to CANN’s over the last 12 months.

CANN's Price Growth Rating (35) in the null industry is in the same range as MEDIF (59). This means that CANN’s stock grew similarly to MEDIF’s over the last 12 months.

CANN's P/E Growth Rating (100) in the null industry is in the same range as MEDIF (100). This means that CANN’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANNMEDIF
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 20 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bullish Trend 6 days ago
87%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CANN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OGI1.650.04
+2.48%
Organigram Global Inc
COHN12.110.12
+1.04%
Cohen & Company
SPG182.250.73
+0.40%
Simon Property Group
TBLA3.370.01
+0.30%
Taboola.com Ltd
VCTR71.45-0.86
-1.19%
Victory Capital Holdings

CANN and

Correlation & Price change

A.I.dvisor tells us that CANN and CVSI have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CANN and CVSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANN
1D Price
Change %
CANN100%
-8.42%
CVSI - CANN
23%
Poorly correlated
+1.70%
MEDIF - CANN
21%
Poorly correlated
-1.26%
CNTMF - CANN
14%
Poorly correlated
-1.82%
CAIHF - CANN
12%
Poorly correlated
N/A
BIOGY - CANN
9%
Poorly correlated
N/A
More

MEDIF and

Correlation & Price change

A.I.dvisor tells us that MEDIF and SWGHF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDIF and SWGHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
-1.26%
SWGHF - MEDIF
29%
Poorly correlated
N/A
GLASF - MEDIF
25%
Poorly correlated
+3.99%
AAWH - MEDIF
23%
Poorly correlated
+6.62%
TCNNF - MEDIF
22%
Poorly correlated
+4.55%
CURLF - MEDIF
22%
Poorly correlated
+1.79%
More